EVALUATION OF THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN FOR TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE UNITED STATES

被引：0
|
作者：
Nechi, R. [1 ]
Rane, A. [2 ]
Karaye, R. [3 ]
Ndikumukiza, C. [2 ]
Alsahali, S. [4 ]
Jatau, A. [5 ]
Zoni, C. R. [6 ]
Alanazi, A. [7 ]
Karaye, I [8 ]
Yunusa, I [9 ]
机构：
[1] Penn State Univ, Hershey, PA USA
[2] MCPHS Univ, Boston, MA USA
[3] Aminu Kano Teaching Hosp, Kano, Nigeria
[4] Qassim Univ, Unaizah Coll Pharm, Dept Pharm Practice, Qasim, Saudi Arabia
[5] Univ Tasmania, Hobart, Tas, Australia
[6] Unconn Hlth, Framingham, CT USA
[7] Massachusetts Coll Pharm & Hlth Sci MCPHS, Dept Pharmaceut Econ & Policy, Sch Pharm, Boston, MA USA
[8] Hofstra Univ, Dept Populat Hlth, Hempstead, NY USA
[9] Univ South Carolina, Columbia, SC USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE342
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [41] COST-OFFSET ANALYSIS OF DAPAGLIFLOZIN IN TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) IN CHINA
    Guan, H.
    Liu, Y.
    Feng, Y.
    He, Y.
    Liu, J.
    [J]. VALUE IN HEALTH, 2021, 24 : S73 - S73
  • [42] Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
    Chia-Te Liao
    Chun-Ting Yang
    Han Siong Toh
    Wei-Ting Chang
    Hung-Yu Chang
    Fang-Hsiu Kuo
    Mei-Chuan Lee
    Yi-Ming Hua
    Hsin-Ju Tang
    Carol Strong
    Huang-Tz Ou
    [J]. Cardiovascular Diabetology, 20
  • [43] COST-EFFECTIVENESS OF DAPAGLIFLOZIN PLUS STANDARD TREATMENT COMPARED TO STANDARD TREATMENT FOR THE MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN COLOMBIA
    Rojas, Gil Y.
    Lasalvia, P.
    Pena, Garcia A. A.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S92 - S92
  • [44] Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice
    Montero-Perez-Barquero, Manuel
    Escobar-Cervantes, Carlos
    Arevalo-Lorido, Jose Carlos
    Conde-Martel, Alicia
    Salamanca-Bautista, Prado
    Manzano-Espinosa, Luis
    Formiga, Francesc
    Diez-Manglano, Jesus
    Cepeda, Jose Maria
    Gonzalez-Franco, Alvaro
    Casado-Cerrada, Jesus
    [J]. FUTURE CARDIOLOGY, 2023, 19 (06) : 343 - 351
  • [45] Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
    Yake Lou
    Tianyang Hu
    Jing Huang
    [J]. American Journal of Cardiovascular Drugs, 2023, 23 : 47 - 57
  • [46] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [47] Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
    Lou, Yake
    Hu, Tianyang
    Huang, Jing
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (01) : 47 - 57
  • [48] A NEW COST-EFFECTIVENESS MODELLING APPROACH IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
    McMurray, J. J.
    Cowie, M. R.
    Cohen, A. A.
    Briggs, A.
    de Pouvourville, G.
    Taylor, M.
    Hancock, E.
    Trueman, D.
    Mumby-Croft, J.
    Haroun, R.
    Deschaseaux, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A394 - A394
  • [49] Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
    Dixit, Neal M.
    Truong, Katie P.
    Vaduganathan, Muthiah
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. JACC-HEART FAILURE, 2024, 12 (07) : 1226 - 1237
  • [50] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S106
12345